文献速递MDS 与骨髓增殖性肿瘤

骨髓增殖性肿瘤新型药物:前进还是倒退的困境与失望

Forging ahead or moving back: dilemmas and disappointments of novel agents for myeloproliferative neoplasms.
PubMed 文献 · Br J Haematol · 2020-03-13

MPN包括ET、PV和MF,临床异质性大,管理需兼顾血栓止血、骨髓衰竭、症状控制及移植与药物权衡。近15年JAK/STAT信号、基因组全景、诊断标准、预后评分及靶向治疗快速进展。本文综述MPN新型药物与治疗策略的成功与失败。

要点

  • MPN管理需兼顾血栓止血、骨髓衰竭、症状控制及移植与药物权衡。
  • 近15年JAK/STAT信号、基因组全景、诊断标准及靶向治疗推动MPN领域进展。
  • 综述总结MPN新型药物与治疗策略的成功与失败。

核心结论

  • 综述总结了MPN新型药物与治疗策略的成功与失败。

研究设计与样本

  • 综述文章,回顾MPN管理中新药与治疗方法的成功与失败。

主要发现

  • 近15年MPN领域在JAK/STAT信号、基因组全景、诊断标准、预后评分及靶向治疗方面快速进展。
  • MPN管理需兼顾血栓止血、骨髓衰竭、症状控制及异基因移植与药物权衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The common 'Philadelphia chromosome'-negative myeloproliferative neoplasms (MPN) comprise essential thrombocythaemia, polycythaemia vera and myelofibrosis. These are clinically diverse disorders and present many challenges during their course, ranging from the management of very indolent, chronic-phase disease through to very aggressive stages frequently associated with poor quality of life, heavy symptom burdens and potentially life expectancies of <18 months. Their management also requires expertise in thrombosis and haemostasis in addition to marrow failure, debilitating symptom control and balancing the 'pros and cons' of intensive therapy such as allogeneic stem cell transplant versus novel and established therapies. In the past 15 years this field has seen rapid advances following an understanding of the pivotal importance of constitutive Janus kinase/signal transducers and activators of transcription (JAK/STAT) signalling, the interplay of the wider genomic landscape and the development of updated diagnostic criteria, prognostic scores and targeted therapies. In this article, we review the successes and failures of novel agents and approaches to MPN management.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. McLornan DP, Harrison CN. Forging ahead or moving back: dilemmas and disappointments of novel agents for myeloproliferative neoplasms. Br J Haematol. 2020. PMID: 32167592. doi:10.1111/bjh.16573

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。